Does Trevi Therapeutics (TRVI) Have the Potential to Rally 102.07% as Wall Street Analysts Expect?

Group 1 - Trevi Therapeutics, Inc. (TRVI) shares have increased by 6.5% over the past four weeks, closing at $10.64, with a mean price target of $21.5 indicating a potential upside of 102.1% [1] - The mean estimate consists of 12 short-term price targets with a standard deviation of $3.26, where the lowest estimate is $16.00 (50.4% increase) and the highest is $27.00 (153.8% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as indicated by a 0.7% increase in the Zacks Consensus Estimate for the current year [11][12] Group 2 - TRVI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13] - While consensus price targets are often viewed as important, they should be approached with skepticism due to historical inaccuracies in predicting actual stock price movements [3][10] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9]